drugset / Trial / NCT07296484
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RandomizedParallel-groupQuadruple-blindOther
Summary
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Timeline
- Start
- 2025-11-29
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | clofutriben | Small molecule | 0.2 mg | Oral |
| Subject | clofutriben | Small molecule | 2 mg | Oral |
| Subject | clofutriben | Small molecule | 6 mg | Oral |
| Subject | clofutriben | Small molecule | 12 mg | Oral |